Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3\textsuperscript{int} CD161 + ROR\gamma t + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies

Juliëtte N. Pouw\textsuperscript{1,2*}, Michel A. M. Olde Nordkamp\textsuperscript{2}, Tessa van Kempen\textsuperscript{3}, Arno N. Concepcion\textsuperscript{2}, Jacob M. van Laar\textsuperscript{1}, Femke van Wijk\textsuperscript{2}, Julia Spierings\textsuperscript{1}, Emmerik F. A. Leijten\textsuperscript{4} & Marianne Boes\textsuperscript{2,5}

In psoriatic arthritis (PsA), predisposing class I HLA alleles, the presence of synovial clonally proliferated CD8+ T cells and autoantibodies all point towards the loss of immune tolerance. However, the key mechanisms that lead to immune dysregulation are not fully understood. In other types of inflammatory arthritis, T regulatory cell (Treg) dysfunction and plasticity at sites of inflammation were suggested to negatively affect peripheral tolerance. We here addressed if Treg variances associate with psoriatic disease. We collected clinical data, sera and peripheral blood mononuclear cells from 13 healthy controls, 21 psoriasis and 21 PsA patients. In addition, we obtained synovial fluid mononuclear cells from 6 PsA patients. We studied characteristics of CD4+ CD25+ CD127loFoxp3+ Tregs by flow cytometry and used ELISA to quantify antibodies against ADAMTSL5, a recently discovered autoantigen in psoriatic disease. In comparison with their circulating counterparts, Tregs from inflamed joints express increased levels of ICOS, CTLA-4 and TIGIT. Furthermore, synovial fluid-derived Tregs have a distinct phenotype, characterized by IL-17A production and upregulation of CD161 and ROR\gamma t. We identified a subset of Tregs with intermediate Foxp3 expression as the major cytokine producer. Furthermore, ICOS+ Tregs associate with PsA disease activity as measured by PASDAS. Lastly, we observed that presence of the Foxp3\textsuperscript{int} Tregs associates with an increased abundance of anti-ADAMTSL5 autoantibodies. Tregs derived from the inflammatory environment of inflamed PsA joints exhibit a distinct phenotype, which associates with loss of peripheral immune tolerance in psoriatic disease.

Abbreviations
ADAMTSL5 A disintegrin and metalloprotease domain containing thrombospondin type 1 motif-like 5
CTLA-4 Cytotoxic T lymphocyte-associated protein 4 (CD152)
DMARD Disease modifying anti-rheumatic drug
ELISA Enzyme-linked immuno sorbent assay
Foxp3 Forkhead box p3
ICOS Inducible T cell costimulator (CD278)
IL Interleukin

\textsuperscript{1}Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, H03.103, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. \textsuperscript{2}Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, 3508 AB Utrecht, The Netherlands. \textsuperscript{3}Biomedical Laboratory Sciences, Avans University of Applied Sciences, 4800 RA Breda, The Netherlands. \textsuperscript{4}Department of Rheumatology, Sint Maartenskliniek, 6500 GM Nijmegen, The Netherlands. \textsuperscript{5}Department of Pediatric Immunology, Wilhelmina Children’s Hospital, Utrecht University, 3508 AB Utrecht, The Netherlands. *email: j.n.pouw-3@umcutrecht.nl
Psoriatic arthritis (PsA) is a heterogeneous, inflammatory, musculoskeletal disease characterized by psoriasis, arthritis, enthesitis, dactylitis and nail dystrophy. PsA is the second most common type of inflammatory arthritis and develops in up to 30% of patients with psoriasis. Increasing evidence suggests that autoimmune mechanisms underlie PsA pathogenesis, including strong associations with class I human leukocyte antigen alleles, ectopic lymphoid neogenesis in synovial tissues with T and B cell aggregates, presence of autoantibodies, and clonally proliferated CD8 + T cells in synovial tissue and fluid. However, the key immunological factors that decrease immune tolerance and lead to PsA transition in psoriasis patients remain largely unknown.

In auto-immune rheumatic diseases, regulatory T cells (Tregs) derived from synovial fluid were shown to effectively suppress effector T cells and thus maintain immune homeostasis. However, other studies implicated Tregs in a pathogenic role, showing data that loss of peripheral immune tolerance associated with impaired expression of key immune regulatory molecules and through Treg differentiation. Tregs in an inflammatory micro-environment may differentiate under the influence of T cell receptor engagement, IL-2 deprivation and pro-inflammatory cytokines. Consequently, Tregs can downregulate their key transcription factor forkhead box P3 (Foxp3) and obtain effector T cell (Teff) phenotype and function. Moreover, Treg differentiation—or plasticity—can be accompanied by reduced suppressive function, expression of T helper 17 cell features (CD161, retinoic acid–related orphan receptor gamma t (ROTy)) and production of pro-inflammatory cytokines. Hence, these results suggest that differentiated Tregs in inflammatory arthritis may become pathogenic and amplify inflammation, instead of halting disease.

With regards to Tregs in patients with psoriatic disease, literature is scarce. Treg abnormalities have been observed, mostly in patients with psoriasis, including decreased expression of CD39 and CD74, increased expression of IL-6Rα, reduced suppressive capacity, chemotactic deficiency and the enhanced propensity to differentiate into cells that produce interleukin (IL)-17—the hallmark cytokine of psoriatic disease. Only few studies investigated the role of Tregs in PsA pathogenesis and in-depth characterization of intra-articular Tregs is lacking. With this study we aimed to study a possible role for Treg phenotypical variances in PsA pathogenesis and loss of peripheral tolerance.

Methods

Study design. We performed an observational cohort study at the University Medical Center Utrecht, the Netherlands. The study protocol was approved by the medical research ethics committee Utrecht (protocol number 13-696). We obtained written informed consent from all participants. The work has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

Subjects. We included patients aged 18 years or older with a diagnosis of psoriasis or PsA. PsA patients met the ‘CIASification for Psoriatic ARthritis’ (CASPAR) criteria. We defined psoriasis as a confirmed diagnosis of psoriasis and absence of inflammatory arthritis. The latter was assessed by medical history, physical examination and laboratory parameters. We excluded patients that used disease-modifying anti-rheumatic drugs (DMARDs) in the past three months. In addition, we collected synovial fluid from patients with a clinical diagnosis of PsA, gout and osteoarthritis (OA).

Disease activity. To quantify disease activity we used two validated, disease-specific composite measures for PsA: Disease Activity Index for PSA (DAPSA) (range 0–164) and Psoriatic Arthritis Disease Activity Score (PASDAS) (range 0–10). We used patient-reported outcomes (PROs) to assess disease severity with six questionnaires: dermatology life quality index, health assessment questionnaire, short form-36 physical and mental component score, visual analogue scale for pain and patient global assessment.

Samples. We performed cross-sectional sampling of peripheral blood and synovial fluid. To collect sera, we centrifuged BD Vacutainer® Plastic Blood Collection serum Tubes (silica and polymer gel) for 10 min (1500 g, room temperature). We collected peripheral blood in BD Vacutainer® Plastic Blood Collection Tubes with Lithium Heparin. For synovial fluid and synovial fluid mononuclear cells (SFMC), we obtained intra-articular fluid of swollen joints in sterile 10–50 mL syringes. We isolated SF by centrifugation for 10 min (2300 g). To isolate PBMC and SFMC we performed 25 min density centrifugation (400 g, Ficoll-Paque). We stored samples at −80 °C (sera, synovial fluid) and liquid nitrogen (PBMC, SFMC) until measurement.

T cell activation assay. To assess Treg cytokine production upon activation, we cultured PBMC and SFMC in complete medium (RPMI 1640 GlutaMAX (61,870,044; Thermo Fisher Scientific) + 10% fetal bovine serum + 1% Penicillin–Streptomycin) with 20 ng/mL PMA (P8139-1MG, Sigma) and 1 µg/mL ionomycin (407,952, Calbiochem / EMD Chemicals inc.) for 4.5 h, while inhibiting protein transport with 1:1000 BD GolgiStop (51-2092KZ, BD Bioscience).
Flow cytometry. We stained samples by incubation with 25 μl antibody mix diluted in buffer (500 ml phosphate-buffered saline + 5 ml 10% sodium azide + 5 g bovine serum albumin) for 25 min at 4°C. Before intracellular staining, we fixed and permeabilized cells with 100 μl Fixation/Permeabilization Concentrate and Diluent (00–5123–43, 00–5223–56, ebioscience). Details of flow cytometry antibodies of both panels used are listed in Supplemental Table S1. Using fluorescence minus one (FMO) controls, we identified viable (assessed by a Fixable Viability Dye) CD3+CD4+CD25+CD127loFoxp3+Tregs. To further study the phenotypical and functional properties of Tregs with reduced expression of Foxp3, we studied Tregs with intermediate (Foxp3int) and high (Foxp3hi) Foxp3 expression. Importantly, we do not propose to have identified two different subsets of Tregs, but use this exploratory dichotomization of the Treg population to enable studying the differences between Tregs with high and intermediate Foxp3 expression. Of these Foxp3int and Foxp3hi Treg subsets, we used FMO controls to assess median fluorescent intensity (MFI) and proportions of cell populations that express cytotoxic T-lymphocyte-associated protein 4 (CTLA-4 = CD152), CD161, inducible T-cell costimulator (ICOS = CD278), T cell immunoreceptor with Ig and ITIM domains (TIGIT), Ki67 and RORyT. In addition to FMO controls, we found that the modest expression of RORyT and CD161 required standardization by using a uniform gate based on a representative healthy control sample of CD3+CD4+CD25+CD127hi Tregs. We standardized quantification of intracellular IL-10 and IL-17A by applying a cutoff value of < 0.5% in the medium control samples. Negative controls of flow cytometry analyses are shown in Supplemental Figure S1 and S2. We performed acquisition on the BD LSRFortessa (405, 488, 561, 635 nm lasers) with BD FACSDIVA (version 8.0.1). We used FlowJo (version 10.7.1) for further analyses.

ELISA. We coated 96-well flat-bottom Nunc MaxiSorp plates (44–2404–21, ThermoFisher) overnight with 50 μl/well 5 μg/mL recombinant ADAMTSL5 peptide (NBP1–93438PEP, Novus Biologicals), diluted in 2% bovine serum albumin (BSA)(10,735,094,001, Roche) in phosphate buffered saline (PBS). Next, we blocked nonspecific binding sites for 1 h at room temperature with 100 μl/well 4% BSA in PBS and incubated overnight with 50 μl serially diluted patient serum or SF in duplo in 2% BSA in PBS. For the standard curve, we used 50 μl primary anti-human ADAMTSL5 antibodies in duplo (HPA044050–100UL, Sigma-Aldrich), serially diluted in 2% BSA in PBS in the following concentrations: 5.00, 1.67, 0.56, 0.1852, 0.0617, 0.0206, 0.0069 μg/mL. After overnight incubation at 4°C, we incubated patient sample wells with 50 μl/well horseradisch-peroxidase (HRP)-conjugated anti-human IgG (11,869,130, ThermoFisher Scientific) and standard curve wells with 50 μl HRP-conjugated anti-rabbit IgG (31,460, Thermofisher). We developed and stopped the color reaction with 50 μl/well of 3,3′, 5,5′-tetramethybenzidine (TMBW–1000–01, Tebu-Bio) and 2 N H2SO4, respectively. We measured absorbance at 450 nm with a reference wavelength of 570 nm. We selected the dilution that best fitted the 5-parameter fit curve using software by Clariostar (version 5.40 R2; firmware version 1.2; serial number 430–1031) and MARS (version 3.31).

Statistical analysis. We applied Wilcoxon Singed Rank tests to compare characteristics between Foxp3int and Foxp3hi Tregs. To compare flow cytometry and ELISA results between patient groups, we used Mann–Whitney U (MWU) tests. Synovial fluid-derived Tregs were only compared with peripheral blood Tregs from PsA patients. To test the association of clinical outcomes, Treg characteristics and autoantibody concentration, we used Spearman’s rank correlation. We performed contingency analyses using χ2 tests for categorical variables, and independent samples T-tests or MWU tests for continuous variables, to analyze patient clinical characteristics. A P-value of <0.05 was considered statistically significant. Statistical analyses were performed with IBM SPSS statistics (Version 26 Release 26.0.0.1) and GraphPad Prism 8 (Version 8.3.0).

Ethics approval and consent to participate. The study protocol was approved by the medical research ethics committee Utrecht (protocol number 13–696). We obtained written informed consent from all participants.

Results Cohort. To investigate Treg phenotypical variances in psoriatic disease, we studied characteristics of Tregs in peripheral blood from 13 healthy controls (HC), 21 psoriasis patients and 21 PsA patients, and in synovial fluid of 6 PsA patients. Detailed patient characteristics are shown in Supplemental Table S2. We identified Tregs using representative healthy control sample of CD3+CD4+CD25+CD127hi Tregs. We standardized quantification of intracellular IL-10 and IL-17A by applying a cutoff value of < 0.5% in the medium control samples. Negative controls of flow cytometry analyses are shown in Supplemental Figure S1 and S2. We performed acquisition on the BD LSRFortessa (405, 488, 561, 635 nm lasers) with BD FACSDIVA (version 8.0.1). We used FlowJo (version 10.7.1) for further analyses.

Increase of CD4+CD25+CD127hiFoxp3+tregs with intermediate Foxp3 expression in PsA synovial fluid. We observed that synovial fluid-derived Tregs, as compared to peripheral blood, have lower expression of Foxp3 (MFI 3248 vs. 4948, P = 0.002)(Fig. 1B). As Foxp3 is the key transcription factor of Treg development, maintenance and function, this finding raised our interest in phenotypical and functional properties of Tregs with reduced expression of Foxp3. Therefore, we studied two subset of Tregs: with intermediate (Foxp3int) and high (Foxp3hi) Foxp3 expression. Importantly, we do not propose to have identified two different subsets of Tregs, but use this exploratory dichotomization of the Treg population to enable studying the differences between Tregs with high and intermediate Foxp3 expression. Of these Foxp3int and Foxp3hi Treg subsets, we used FMO controls to assess median fluorescent intensity (MFI) and proportions of cell populations that express cytotoxic T-lymphocyte-associated protein 4 (CTLA-4 = CD152), CD161, inducible T-cell costimulator (ICOS = CD278), T cell immunoreceptor with Ig and ITIM domains (TIGIT), Ki67 and RORyT. In addition to FMO controls, we found that the modest expression of RORyT and CD161 required standardization by using a uniform gate based on a representative healthy control sample of CD3+CD4+CD25+CD127hi Tregs. We standardized quantification of intracellular IL-10 and IL-17A by applying a cutoff value of < 0.5% in the medium control samples. Negative controls of flow cytometry analyses are shown in Supplemental Figure S1 and S2. We performed acquisition on the BD LSRFortessa (405, 488, 561, 635 nm lasers) with BD FACSDIVA (version 8.0.1). We used FlowJo (version 10.7.1) for further analyses.
Figure 1. Increase of Tregs with intermediate Foxp3 expression in inflamed PsA joints. Flow cytometry analysis of Foxp3 expression by CD4+CD25+CD127lo T cells derived from peripheral blood of HC (n = 13), psoriasis patients (n = 21) and PsA patients (n = 20), and from synovial fluid of PsA patients (n = 6). Bar graphs: symbols represent individual subjects; bars show median with interquartile range; *P value < 0.05 (PsA synovial fluid only compared with PsA peripheral blood). (A) Gating strategy for CD4+CD25+CD127loFoxp3+ Tregs. We differentiated between Tregs with intermediate and high expression of Foxp3 (Foxp3int and Foxp3hi, respectively). Percentages in dot plots represent median of peripheral blood-derived Tregs in PsA. (B) Foxp3 expression by CD4+CD25+CD127lo T cells. (C) Proportion of Foxp3int and Foxp3hi Tregs of CD4+CD25+CD127lo T cells. Foxp3int/hi: forkhead box P3 expression intermediate / high; FSC-A: forward scatter area; FSC-H: forward scatter height; HC: healthy control; MFI: median fluorescent intensity; PsA: psoriatic arthritis; PsO: psoriasis; SSC-A: sideward scatter area; Treg: T regulatory cell.
**Figure 2.** CD161 + RORγt + phenotype of synovial fluid-derived Foxp3<sup>int</sup> and Foxp3<sup>hi</sup> Tregs. Flow cytometry analysis of CD4 + CD25 + CD127<sup>lo</sup>Foxp3 + Tregs derived from peripheral blood of HC (n = 13), psoriasis patients (n = 21) and PsA patients (n = 20), and from synovial fluid of PsA patients (n = 6). Bar graphs: symbols represent individual subjects; bars show median with interquartile range; *P* value < 0.05 (synovial fluid only compared with PsA peripheral blood). Dot plots: percentages in PBMC plots represent median of PB-derived Tregs in PsA; percentages in SFMC plots represent median of SF-derived Tregs. (A) Proportions of CD161 + Foxp3<sup>int</sup> and CD161 + Foxp3<sup>hi</sup> Tregs. (B–C) Representative flow cytometry plots to identify CD161 + Foxp3<sup>int</sup> and -Foxp3<sup>hi</sup> Tregs derived from peripheral blood (B) and synovial fluid (C). (D) Proportions of RORγt + Foxp3<sup>int</sup> and RORγt + Foxp3<sup>hi</sup> Tregs. (E–F) Representative flow cytometry plots to identify RORγt + Foxp3<sup>int</sup> and -Foxp3<sup>hi</sup> Tregs derived from peripheral blood (E) and synovial fluid (F). Foxp3<sup>int</sup>/hi: forkhead box P3 expression intermediate/high; HC: healthy control; PBMC: peripheral blood mononuclear cells; PsA: psoriatic arthritis; PsO: psoriasis; RORγt: retinoic acid receptor-related orphan receptor gamma; SFMC: synovial fluid mononuclear cells; Tregs: T regulatory cells.
Peripheral Blood Synovial Fluid

A

IL-10 (all Tregs)

% of CD4+CD25+CD127loFoxp3+ T cells

B

IL-10 (per Treg subset)

% of CD4+CD25+CD127loFoxp3+ T cells

C

PBMC

Foxp3int Tregs

Foxp3hi Tregs

D

SFMC

Foxp3int Tregs

Foxp3hi Tregs

E

IL-17A (all Tregs)

% of CD4+CD25+CD127loFoxp3+ T cells

F

IL-17A (per Treg subset)

% of CD4+CD25+CD127loFoxp3+ T cells

G

PBMC

Foxp3int Tregs

Foxp3hi Tregs

H

SFMC

Foxp3int Tregs

Foxp3hi Tregs
Proportion of CD4+ CD25+ CD127loFoxp3+ Tregs, that upon activation produce IL-17A. Moreover, we observed higher CTLA-4 and TIGIT expression by Foxp3int Tregs of PsA patients as compared to healthy controls, psoriasis and PsA patients.

A subset of tregs in inflamed joints in PsA upregulate CD161 and RORyt. To further investigate the phenotype of Foxp3int and Foxp3hi synovial fluid-derived Tregs in PsA we studied CD161 and RORyt, as they are associated with arthritis and a pro-inflammatory potential of Tregs. In PsA patients, we found that the percentage of CD161-expressing Tregs was higher in synovial fluid than in circulation and that more Foxp3hi Tregs express CD161 (4.1%), as compared to Foxp3hi Tregs (1.3%) (Fig. 2A–C). Additionally, in PsA, synovial fluid Tregs express more RORyt than Tregs in circulation (Foxp3int 3.0% vs. 1.0%, P = 0.048; Foxp3hi 1.8% vs. 0.5% Treg, P = 0.026) (Fig. 2D–F). The increased expression of CD161 and RORyt by synovial Tregs was most pronounced in the intermediate Foxp3 subset of Tregs (Fig. 2A and D). Again, no differences were found between peripheral blood Tregs of healthy controls, psoriasis and PsA patients.

High IL-10 and IL-17A production by synovial fluid-derived tregs. To study functional differences between Tregs in an inflammatory environment and in circulation of PsA patients, we measured inhibitory and pro-inflammatory cytokine production. As expected, Tregs from synovial fluid showed a modest but increased capacity to produce cytokines, both the anti-inflammatory cytokine IL-10 (3.7% vs. 1.8%, P < 0.001) (Fig. 3A) and the key pro-inflammatory cytokine IL-17A (3.2% vs. 1.7%; P = 0.002) (Fig. 3E). Moreover, Tregs from PsA patients produce less IL-10, as compared to psoriasis patients (Fig. 3A and B). When examining the different subsets of Tregs, we found that the Foxp3int subset was the major cytokine producer, the most notable being the elevated IL-17A producing capacity by Foxp3int synovial fluid Tregs (5.9% vs. 1.2%, P = 0.028) (Fig. 3B and 3F–H). We observed that—both in peripheral blood and in synovial fluid—PsA patients have a higher proportion of single-IL-17A cytokine-producing Tregs as compared to healthy controls and psoriasis patients. A minority of Tregs produce both IL-10 and IL-17A (Supplemental Figure S5).

Synovial fluid-derived tregs express high CTLA-4, TIGIT and ICOS. Reduced expression of immune receptors by Tregs could contribute to abnormal Treg function in inflammatory arthritis. Therefore, we measured expression of two key inhibitory receptors essential for Treg suppressive function: CTLA-4 and TIGIT (Fig. 4A–F). Both receptors were expressed more by Foxp3hi Tregs, as compared to the intermediate Treg subset (Fig. 4A and D). In PsA patients, the proportions Tregs that express CTLA-4 were increased in synovial fluid, as compared to peripheral blood (Foxp3int 23.5% vs. 3.3%, P = 0.000; Foxp3hi 28.6% vs. 7.4%, P = 0.003) (Fig. 4A–C). That was similar for TIGIT; proportions of Foxp3int and Foxp3hi Tregs with TIGIT expression were higher in synovial fluid (Foxp3int 85.3% vs. 69.1%, P = 0.002; Foxp3hi 90.3% vs. 78.0%, P = 0.004) (Fig. 4D–F). Moreover, we observed higher CTLA-4 and TIGIT expression by Foxp3int Tregs of PsA patients as compared to psoriasis patients (CTLA-4 + Tregs: 2.3% vs. 3.3%, P= 0.040; TIGIT + Tregs: 63.2% vs. 69.1%, P = 0.017) (Fig. 4A and B).

Moreover, we included ICOS in our phenotypical Treg characterization, because ICOS + Tregs can play a pro-inflammatory, pathogenic role in inflammatory arthritis and immune diseases. We observed a comparable expression pattern as for the inhibitory receptors: synovial fluid-derived Tregs express more ICOS, as compared to Tregs in circulation (Fig. 5A–D). Furthermore, we found a difference between the Foxp3int and Foxp3hi Treg subsets: in peripheral blood Foxp3int Tregs express less ICOS as compared to Foxp3hi Tregs (3.5% vs. 8.6%, P = 0.000), but in synovial fluid both subset express similar levels (10.3% vs. 13.0%, P = 0.753) (Fig. 5A). This is a relevant finding, because we observed an association of ICOS expression on Treg with PsA disease activity as measured by PASDAS (range 0–10), which takes arthritis, enthesisitis, dactylitis, C-reactive protein, physician disease activity score and two PROs into account (Fig. 5E). Both the proportion of ICOS + Tregs and the MFI of ICOS
significantly correlated with PASDAS in the Foxp3\textsuperscript{int} Treg subset and the Foxp3\textsuperscript{hi} Treg subset. No significant differences were found between healthy controls, psoriasis and PsA patients.

**ADAMTSL5 autoantibodies associate with treg Foxp3 expression in psoriatic disease.** Lastly, we queried whether Treg phenotypical variances are associated with loss of peripheral tolerance in PsA. To investigate this further, we quantified autoantibodies in serum and synovial fluid against a newly discovered autoantigen specific for psoriatic disease: A Disintegrin And Metalloprotease domain containing Thrombospondin type 1 motif-Like 5 (ADAMTSL5) (patient characteristics shown in Supplemental Table S3 and S4)\textsuperscript{33}. ADAMTSL5 is a protein present in extracellular matrix and implicated in microfibril function modulation\textsuperscript{34}. We observed higher anti-ADAMTSL5 IgG in PsA serum (575 ± 1523 µg/mL (IQR 321–1523)), as compared to HC serum (205 ± 645 µg/mL (IQR 103–645), P = 0.012) and PsA synovial fluid (138 ± 645 µg/mL (IQR 77–348), P < 0.0001)(Fig. 6A). ADAMTSL5 autoantibodies discriminated between psoriasis and PsA diagnosis with an AUROC of 0.67 (95%CI 0.543–0.787), P = 0.012 (Supplemental Figure S6B). No associations of anti-ADAMTSL5 IgG with clinical characteristics or disease activity were observed (data not shown).

Further, we identified an association of Foxp3 instability with autoantibody production in psoriatic disease. We observed that the Foxp3\textsuperscript{int} Treg subset correlated with the presence of ADAMTSL5 autoantibodies in peripheral blood of patients with psoriatic disease (Spearman’s rho (ρ) 0.466, P = 0.002)(Fig. 6B). The correlation was even stronger in PsA alone (ρ 0.606, P = 0.005)(Fig. 6C). In contrast, we observed an inverse correlation of Foxp3\textsuperscript{hi} Tregs with anti-ADAMTSL5 IgG in psoriatic disease (ρ -0.380, P = 0.014)(Fig. 6D), again more pronounced in PsA alone (ρ -0.528, P = 0.017)(Fig. 6E). Absence of a correlation in healthy controls suggests that the association of Foxp3 expression by Tregs with ADAMTSL5 autoantibodies is specific for psoriatic disease (Supplemental Figure S7).

**Discussion**

In the inflammatory microenvironment of autoimmune disease, Treg defects and differentiation are suggested to play a role in loss of peripheral immune tolerance. However, the implications of Treg dysfunction and plasticity have not been clarified in psoriatic disease. To our knowledge, this is the first study to perform in-depth phenotypical characterization of Tregs derived from the inflammatory microenvironment of inflamed joints in patients with psoriatic disease. Here, we provide evidence for Treg variance in PsA by showing distinct phenotypical and functional properties of intra-articular Tregs as compared to Tregs in circulation: downregulation of key transcription factor Foxp3, increased cytokine production, upregulation of inhibitory immune receptors, and upregulation of markers that have been reported to associate with a pro-inflammatory potential of Tregs: CD161, RORγt and ICOS\textsuperscript{7,14,15,30,31,37–39}.

Foxp3 is the key transcription factor of Tregs and its expression is essential for Treg development, maintenance and function\textsuperscript{29}. Our results demonstrate a significant increase of intra-articular Tregs with intermediate Foxp3 expression in PsA patients. Association of Foxp3 with PsA has been previously described by one study, that identified a hemizygous Foxp3 mutation (c.1222G > A) in familial juvenile PsA\textsuperscript{35}. Moreover, in psoriasis patients, it was shown that enhanced loss of Foxp3 is linked to Treg differentiation into IL-17A producing cells\textsuperscript{36}. In the broader context of autoimmune disease, multiple studies suggested that stability of Foxp3 expression is negatively affected by pro-inflammatory conditions\textsuperscript{13,19}. These findings have clinical relevance, because Treg defects—including Foxp3 instability—could contribute to disease pathophysiology. This contribution is either through increased escape of autoreactive T cells from Treg regulation or, what has been suggested more recently, by conversion of Tregs into autoreactive, memory T cells\textsuperscript{13,32–38}.

Furthermore, we show that the intra-articular subset of Tregs with lower Foxp3, as compared to their Foxp3\textsuperscript{hi} counterparts in the same tissue location, have lower expression of the inhibitory receptors CTLA-4 and TIGIT. These Foxp3\textsuperscript{int} Tregs produce even more of the psoriatic disease hallmark cytokine IL-17, and display the highest pro-inflammatory activity \textsuperscript{(data not shown)} (Supplemental Figure S7).

In line with the homeostatic importance of Tregs in psoriatic disease, we observed a relation of Foxp3 expression associates with IL-17A producing Tregs in psoriasis\textsuperscript{15}. These findings are not surprising, considering that Foxp3\textsuperscript{hi} Tregs in inflammatory arthritis\textsuperscript{8}. In addition, CD161 + Tregs were previously identified as a subset capable of IL-17A and IFNγ production, and to exhibit a pro-inflammatory potential\textsuperscript{7,30}. In fact, CD161 + Tregs are the predominant IL-17 + RORγt + Tregs to suppress autologous T cell proliferation is reduced by approximately 60%\textsuperscript{14}. Also, RORγt expression associates with IL-17A producing Tregs in psoriasis\textsuperscript{37}. These findings are not surprising, considering that Foxp3 and RORγt transcription factors drive differentiation of T cells towards Th17 cells\textsuperscript{38}. With regards to functional differences, intra-articular Tregs may contribute to ongoing localized inflammation by increased production of IL-17A, as compared to peripheral Tregs. IL-17 has previously been associated with unresponsiveness of T cells in the microenvironment of inflammatory arthritis\textsuperscript{39}. Taken together, we identified a distinct phenotype of synovial fluid-derived Tregs, most pronounced in the Treg subset with downregulated
Figure 4. High expression of key regulatory immune receptors by intra-articular Tregs in PsA. Flow cytometry analysis of CD4+CD25+CD127loFoxp3+ Tregs derived from peripheral blood of HC (n = 13), psoriasis patients (n = 21) and PsA patients (n = 21), and from synovial fluid of PsA patients (n = 6). Bar graphs: symbols represent individual subjects; bars show median with interquartile range; *P value < 0.05 (synovial fluid only compared with PsA peripheral blood). Dot plots: percentages in PBMC plots represent median of PB-derived Tregs in PsA; percentages in SFMC plots represent median of SF-derived Tregs. (A) Proportion of CTLA-4+Foxp3int and CTLA-4+Foxp3hi Tregs. (B,C) Representative flow cytometry plots to identify CTLA-4+Foxp3int and -Foxp3hi Tregs derived from peripheral blood (B) and synovial fluid (C). (D) Proportions of TIGIT+Foxp3int and TIGIT+Foxp3hi Tregs. (E,F) Representative flow cytometry plots to identify TIGIT+Foxp3int and -Foxp3hi Tregs derived from peripheral blood (E) and synovial fluid (F). CTLA-4: cytotoxic T-lymphocyte-associated protein 4 (CD152); Foxp3: forkhead box P3 expression intermediate/high; HC: healthy control; PBMC: peripheral blood mononuclear cells; PsA: psoriatic arthritis; PsO: psoriasis; SFMC: synovial fluid mononuclear cells; TIGIT: T cell immunoreceptor with Ig and ITIM domains; Tregs: T regulatory cells.
[Image of graphs and plots showing the relationship between ICOS expression and Foxp3 levels in peripheral blood and synovial fluid samples from HC, PsO, and PsA patients. The plots include scatter plots and box plots illustrating the distribution of ICOS+ Tregs and ICOS MFI (Mean Fluorescence Intensity) for both Foxp3int and Foxp3hi Tregs. Significant correlations are indicated with p-values and asterisks.]
and spondyloarthritis, associations were found of ICOS expression by Tregs with high disease activity, with ICOS + Foxp3int and -Foxp3hi Tregs derived from peripheral blood. Moreover, evidence suggested that sustained resistance of local CD4+ and CD8+ Teff in an inflammatory microenvironment could be key to ineffective Treg suppression. Whether these mechanisms play a role in psoriatic disease has yet to be elucidated. In the case that an important role for Tregs derived from synovial fluid mononuclear cells, and future studies to confirm our results are warranted. However, we deem that the evident observed dissimilarities between Tregs derived from synovial fluid and peripheral blood have enabled us to draw conclusions about Treg variances. Second, the use of DMARDs (methotrexate and golimumab) by two patients in our SFMC cohort could have influenced our results, although contradicting results have been published as to whether DMARDs affect Treg phenotype and function. Third, we have not assessed the pro-inflammatory potential of Tregs in functional experiments or performed assays to evaluate the suppressive capacity of intra-articular Tregs. Fourth, with flow cytometry analyses we could only assess relative differences. Hence, we can only speculate about the implications of absolute numbers of this distinct subset of Tregs in PsA pathogenesis. Fifth, we observed markedly lower Treg CD161 expression as compared to literature, which may be the result of our gating strategy that selected only Foxp3+ CD25+ CD127lo T cells in an attempt to exclude activated non-Treg T cells with low Foxp3 expression. Moreover, this gating strategy might have resulted in the inclusion of a minor subset of effector T cells, that upon activation might transiently express CD25 and Foxp3. Nevertheless, based on what is known from literature in other types of inflammatory arthritis, we deem to have identified an interesting Treg subset that warrants further investigation.

Since we have not confirmed our hypothesis by assessing the suppressive capacity of intra-articular Tregs, it must be taken into consideration that even differentiated Tregs may be able to effectively suppress Teff. If how differentiated Tregs in inflammatory arthritis can effectively suppress Teff T cells is an increasing topic of interest and contradicting results have been published. Some concluded that impaired expression of immune regulatory molecules or lack of cytokine production are key to defective Teff suppression by Tregs. Others attributed failure of effective Teff suppression to the factor that Tregs are prone to apoptosis under inflammatory conditions. Moreover, evidence suggested that sustained resistance of local CD4+ and CD8+ Teff in an inflammatory microenvironment could be key to ineffective Treg suppression. Whether these mechanisms play a role in psoriatic disease has yet to be elucidated. In the case that an important role for Tregs derived from sites of inflammation in PsA pathogenesis is confirmed, this may facilitate identification of new treatment targets and therapies, including Treg growth factors, Treg stabilizing factors and therapies that enhance Treg function. In preclinical models and clinical trials low dose IL-2 and cellular therapy with polyclonal, therapeutic Tregs have already shown promising results. Moreover, research to artificially stabilize Treg Foxp3 expression in vitro for clinical applications are ongoing. As treatment options for autoimmune disease are evolving, we deem it essential to further advance our understanding of the role of Tregs in psoriatic disease pathogenesis.

Conclusions

In conclusion, we show that Tregs derived from the inflammatory environment of inflamed joints in PsA patients exhibit a distinct phenotype characterized by increased expression of CD161, RORyt and ICOS. Moreover, we identify the importance of Foxp3 expression by Tregs, with a novel role for Foxp3int Tregs with a heightened capacity to produce IL-17A.
**Figure 6.** Foxp3 downregulation by Tregs associates with ADAMTSL5 autoantibodies in psoriatic disease. Association of ADAMTSL5 autoantibodies as measured by ELISA with Foxp3 expression by Tregs as measured by flow cytometry. (A) ELISA of anti-ADAMTSL5 IgG in sera of HC (n = 35), psoriasis patients (n = 39), PsA patients (n = 39), and synovial fluid of PsA patients (n = 43). *P value < 0.05. (B–E) Scatterplots of significant Spearman’s rank correlation of serum anti-ADAMTSL5 autoantibody concentration with Foxp3 expression by CD3 + CD4 + CD25 + CD127lo T cells derived from peripheral blood of psoriasis (n = 21) and PsA patients (n = 20). Differentiation between Foxp3int (B, C) and Foxp3hi (D, E) Tregs in patients with psoriatic disease (B, D) versus PsA patients only (C, E). ADAMTSL5: A Disintegrin And Metalloprotease domain containing ThromboSpondin type 1 motif-Like 5; Foxp3int/hi: forkhead box P3 expression intermediate/high; HC: healthy control; IgG: Immunoglobulin G; P: p value; PsA: psoriatic arthritis; PsO: psoriasis; ρ: Spearman’s rho.
Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Received: 18 July 2022; Accepted: 22 November 2022
Published online: 30 November 2022

References

1. FitzGerald, O. et al. Psoriatic arthritis. Nat. Rev. Dis. Prim. https://doi.org/10.1038/s41572-021-00293-y (2021).
2. Chimenti, M. S. et al. Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease. Autoimmun. Rev. 18, 565–575 (2019).
3. Generali, E., Bose, T., Selmi, C., Voncken, J. W. & Damoiseaux, J. G. M. C. Nature versus nurture in the spectrum of rheumatic diseases: Classification of spondyloarthritis as autoimmune or autoinflammatory. Autoimmun. Rev. 17, 935–941 (2018).
4. Penkava, F. et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8+ T cells expressing tissue-homing receptors in psoriatic arthritis. Nat. Commun. https://doi.org/10.1038/s41467-020-18513-6 (2020).
5. Veale, D. J. & Fearon, U. Psoriatic arthritis 1 The pathogenesis of psoriatic arthritis. Lancet 391, 2273–2284 (2018).
6. Mijnheer, G. et al. Conserved human effector Treg cell transcriptional and epigenetic signature in arthritic joint inflammation. Nat. Commun. 12, 2710 (2021).
7. Afzali, B. et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur. J. Immunol. 43, 2043–2054 (2013).
8. Flores-Borja, F., Jury, E. C., Mauri, C. & Ehrenstein, M. R. Defects in CTLA-4 are associated with abnormal regulatory T cell function. Proc. Natl. Acad. Sci. USA. 108, 16717–16722 (2011).
9. Komatsu, N. et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20, 62–68 (2014).
10. Macdonald, K. G. et al. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J. Allergy Clin. Immunol. 135, 946–955.e9 (2015).
11. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA. 105, 19396–19401 (2008).
12. Beavis, P. A. et al. Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc. Natl. Acad. Sci. USA. 108, 16717–16722 (2011).
13. Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000–1007 (2009).
14. Ueno, A. et al. Increased prevalence of circulating novel IL-17-secreting Foxp3+ CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory T cells support plasticity between TH17 and regulatory T cells in inflammatory bowel disease patients. Inflamm. Bowel Dis. 19, 2522–2534 (2013).
15. Bovenschen, H. J. et al. Foxp3 regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J. Invest. Dermatol. 131, 1853–1860 (2011).
16. Duurland, C. L., Brown, C. C., O'Shaughnessy, R. F. L. & Wedderburn, L. R. CD161+ Tconv and CD161+ treg share a transcriptional and functional phenotype despite limited overlap in TCRβ repertoire. Front. Immunol. 8, 1–18 (2017).
17. Yang, B. H. et al. Foxp3+ T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation. Mucosal Immunol. 9, 444–457 (2016).
18. Mijnheer, G. & Van Wijk, F. T-cell compartmentalization and functional adaptation in autoimmune inflammation: Lessons from rheumatological diseases. Front. Immunol. 10, 1–11 (2019).
19. Shevryev, D. & Tereshchenko, V. Treg heterogeneity, function, and homeostasis. Front. Immunol. 10, 1–13 (2020).
20. Han, L. et al. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4+CD25highFoxp3+ regulatory T-cells in psoriasis. Australas J. Dermatol. 59, e31–e38 (2018).
21. Fiocco, U. et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin. Rheumatol. 34, 1571–1580 (2015).
22. Sugiyama, H. et al. Dysfunctional blood and tissue target CD4+ CD25 high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174, 164–173 (2005).
23. Yan, K. X. et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br. J. Dermatol. 163, 48–56 (2010).
24. Szemtetry, A. et al. Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis. Arthritis Res. Ther. 19, 158 (2017).
25. Soler, D. C. et al. Psoriasis patients exhibit impairment of the high potency CCR5+ T regulatory cell subset. Clin. Immunol. 149, 111–118 (2013).
26. Scher, J. U., Ogdie, A., Merola, J. F. & Ritchlin, C. Preventing psoriatic arthritis: Focusing on patients with psoriasis at increased risk of transition. Nat. Rev. Rheumatol. 15, 153–166 (2019).
27. Yu, N. et al. CD4+CD25+CD127low/-: T cells: A more specific treg population in human peripheral blood. Inflammation 35, 1773–1780 (2012).
28. Liu, W. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203, 1701–1711 (2006).
29. Vignali, D. A. A., Collison, L. W. & Workman, C. J. How regulatory T cells work. Nat. Rev. Immunol. 8, 523–532 (2008).
30. Pesenacker, A. M. et al. Dysregulated ICOS+ proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis. Exp. Ther. Med. 16, 3728–3734 (2018).
31. Li, D. Y. & Xiong, X. Z. ICOS+ Tregs: A functional subset of tregs in immune diseases. J. Allergy Clin. Immunol. 121, 935–941 (2017).
32. Alzyoud, R. et al. Familial clustering of juvenile psoriatic arthritis associated with a hemizygous FOXP3 mutation. Curr. Rheumatol. Rep. 23, 64 (2021).
33. Yang, X. O. et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29, 44–56 (2008).
34. Liu, Y. et al. Elevated circulating CD4+ICOS+Foxp3+ T cells contribute to overproduction of IL-10 and are correlated with disease severity in patients with systemic lupus erythematosus. Lupus 20, 620–627 (2011).
35. Slaunwhite, D. et al. Association of a type 2–polarized T cell phenotype with methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheumatol. 70, 1091–1102 (2020).
39. Araujo, L. M. et al. Increased production of interleukin-17 over interleukin-10 by treg cells implicates inducible costimulator molecule in experimental spondyloarthritis. *Arthritis Rheumatol.* **66**, 2412–2422 (2014).
40. Cribs, A. P. et al. Methotrexate restores regulatory T cell function through demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. *Arthritis Rheumatol.* **67**(3), 1182–1192 (2015).
41. Meyer, A. et al. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors. *Ann. Rheum. Dis.* **80**, 6–7 (2019).
42. Oh, J. S. et al. The effect of various disease-modifying anti-rheumatic drugs on the suppressive function of CD4+CD25+ regulatory T cells. *Rheumatol. Int.* **33**, 381–388 (2013).
43. Kniecik, M. et al. Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. *J. Transl. Med.* **7**, 89 (2009).
44. Liu, Y., Jarjour, W., Olsen, N. & Zheng, S. G. Traitor or warrior–Treg cells sneaking into the lesions of psoriatic arthritis. *Clin. Immunol.* **215**, 108425 (2020).
45. Appel, H. et al. Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. *J. Rheumatol.* **38**, 2445–2451 (2011).
46. Bluestone, J. A. & Tang, Q. T reg cells—the next frontier of cell therapy. *Science* **362**, 154–155 (2018).
47. Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. *Ann. Rheum. Dis.* **78**, 209–217 (2019).
48. Rana, J. & Biswas, M. Regulatory T cell therapy: Current and future design perspectives. *Cell Immunol.* **356**, 104193 (2020).
49. Someya, K. et al. Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation. *Int. Immunol.* **29**, 365–375 (2017).

**Acknowledgements**

We would like to thank all patients who participated in the study. Also, we thank the clinical study team for the collection of samples and clinical data: Anneloes van Loos, Karin Schrijvers, Joke Nijjdeken, Anne Karien Marijnisen, Nanette Vincken and Nienke Kleiarenink. Furthermore, we thank Marlot van der Wal for her contribution to our flow cytometry panels. Lastly, we thank Rinke Nieuwschepen for providing us with a review of literature on Treg phenotype and function in psoriatic disease.

**Author contributions**

J.P., E.L. and MB initiated the study. J.P., E.L., M.O. and T.V.K. isolated sera and PBMC samples. E.L., M.O. and A.C. were responsible for synovial fluid and SFMC collection. J.P. and M.O. performed ELISA and flow cytometry experiments. J.P., E.L., J.S. and M.B. primarily wrote the manuscript. All authors contributed to substantial discussion of content, reviewing and revising the manuscript before submission.

**Funding**

We received no grants from funding agencies in the public, commercial, or not-for-profit sectors.

**Competing interests**

JvL received honoraria from Abbvie, AstraZeneca, Boehringer Ingelheim, Celltrion, Galapagos and Magenta, Roche, and received research grants from AstraZeneca, Boehringer Ingelheim, Roche and Thermofischer. FvW reports grants from investigator initiated studies from Regeneron, Leo Pharma, and Galapagos, a collaboration study with Takeda, and consultant/speaker fees from Takeda and Johnson&Johnson, all outside the submitted work. JS received research grants from Boehringer Ingelheim and Miltenyi. MR reports research grants from Actuate Therapeutics, Nutricia and Argenx, unrelated to the submitted work. All other authors state no conflict of interest and have no disclosures.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-24924-w.

**Correspondence** and requests for materials should be addressed to J.N.P.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022, corrected publication 2023